Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in acute ischemic stroke
NCT05403866Phase 2Completed
- Sponsor
- Lumosa Therapeutics
- Start
- Aug 2022
- Primary completion
- May 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odatroltide in ischemic stroke, sponsored by Lumosa Therapeutics. Started Aug 2022; status: completed.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05403866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403866.